Please login to the form below

Biogen

This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.

Biogen loses another pipeline drug to toxicity concerns

Follows discontinuation of Eisai-partnered Alzheimer's drug. Just a few days after calling time on its Eisai-partnered Alzheimer’s drug elenbecestat, Biogen has another pipeline casualty – this time its ... He added however that “it does

Latest news

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Latest blow in string of failures for BACE inhibitor category. In a potential final blow to the BACE inhibitor treatment category, Biogen and Eisai have discontinued trials of elenbecestat after the ... Biogen and Eisai also had to pull the plug on
J&J’s ponesimiod tops Aubagio in head-to-head MS trial

Revenue prospects for ponesimid are tough to predict, as it is entering an increasingly crowded market for MS therapies, with a range of blockbuster oral therapies already available including Biogen’s ... So far Novartis and Biogen have been able to
Merck takes evobrutinib for MS into phase 3, on mixed data

If successful, Merck will have a chance to bring forward a new-mechanism therapy for relapsing MS that will compete with blockbuster oral drugs such as Biogen’s Tecfidera (dimethyl fumarate), ... It will also have to contend with newer drugs like
Novartis expands its generics franchise with natalizumab biosimilar

Says affordability is a challenge to access. Sandoz, Novartis’ generics unit, has agreed to license a biosimilar of Biogen’s Tysabri for multiple sclerosis from Polpharma Biologics. .
Second TULIP trial resurrects AZ’s lupus drug anifrolumab

Benlysta has been a rare success in lupus, with a string of other drug candidates failing to show activity in trials, including most recently Biogen and UCB’s anti-CD40 drug

More from news
Approximately 110 fully matching, plus 289 partially matching documents found.

Latest Intelligence

Detecting Alzheimer’s ahead of a cure

Biogen and Eisai also pulled the plug on their Alzheimer’s drug aducanumab, after advice from an independent data monitoring committee forced them to abandon the phase 3 Abeta-targeting candidate.
Bluebird: on a mission to ‘recode’ the DNA of healthcare

Nightstar was bought by Biogen for $800m in March.
#OrkambiNow?

But Orkambi is not the only orphan disease drug stuck in market access limbo in the England – Biogen’s Spinraza and BioMarin’s Kuvan are both currently suffering similar fates, and
Where next in Alzheimer’s disease R&D?

Another crushing blow to hopes came on 21 March, when Biogen and Eisai pulled the plug on their phase 3 Abeta-targeting aducanumab. ... N.B. This article was updated on 21 March 2019 following news of Biogen and Eisai's termination of the aducanumab
Drug launches to watch in 2019

only other SMA treatment available, Biogen’s Spinraza.

More from intelligence
Approximately 1 fully matching, plus 39 partially matching documents found.

Latest appointments

BMS appoints new commercial leader, Davies joins Eisai and more

operations. She joins Sobi from Biogen, where she served as vice president for global supply chain operations and strategic partnerships.
Biogen appoints executive VP, corporate development

Biogen has appointed Daniel Karp as its executive vice president, corporate development effective 11 June. ... He will also become a member of the executive committee and will report directly to chief executive officer Michel Vounatsos, who said: “We
Gamida Cell strengthens leadership team

Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.
Editas Medicine names James Mullen as chairman

Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.
Acumen appoints new strategy director

Thomas Bols will focus on reinforcing Acumen’s healthcare practice

More from appointments
Approximately 16 fully matching, plus 32 partially matching documents found.

Latest from PMHub

Healthcircle

Biogen. Chugai. Eisai. Helsinn. Ipsen. Johnson &Johnson. Lundbeck. Medtronic. Mentholatum. Novartis.
Attigo (part of the Mednet Group)

Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK.
IGNIFI

Allergan. Biogen. Boehringer Ingelheim. CO.DON. Danone Nutricia. Ferring Pharmaceuticals. Kyowa Kirin.
Wallace Health

Our expertise spans healthcare providers, pharmaceuticals and consumer health and we work for clients including HCA Hospitals, Alliance Medical, GSK and Biogen as well as high-performing start-ups such as
Bedrock Group

Abbvie. Baxalta. Baxter. Biogen. BMS. Britannia. CareFusion. Celgene. Ipsen. Janssen. Novartis.